Trial Profile
Efficacy and Safety of PegIntron [peginterferon alfa 2b] Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 27 Jan 2012 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 27 Jan 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Aug 2008 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.